journal article·2023-02-09Open access

Copper-induced injectable hydrogel with nitric oxide for enhanced immunotherapy by amplifying immunogenic cell death and regulating cancer associated fibroblasts

Shuilin Shen, Zimeng Zhang, Haixiao Huang, Jing Yang, Xinyue Tao, Zhengjie Meng, Hao Ren, Xueming Li

Biomaterials Research· Volume 27· Issue 1

Abstract

Background Immunogenic cell death (ICD) induced by different cancer treatments has been widely evaluated to recruit immune cells and trigger the specific antitumor immunity. However, cancer associated fibroblasts (CAFs) can hinder the invasion of immune cells and polarize the recruited monocytes to M2-type macrophages, which greatly restrict the efficacy of immunotherapy (IT). Methods In this study, an injectable hydrogel induced by copper (Cu) has been designed to contain antibody of PD-L1 and nitric oxide (NO) donor. The therapeutic efficacy of hydrogel was studied in 4T1 cells and CAFs in vitro and 4T1 tumor-bearing mice in vivo. The immune effects on cytotoxic T lymphocytes, dendritic cells (DCs) and macrophages were analyzed by flow cytometry. Enzyme-linked immunosorbent assay, immunofluorescence and transcriptome analyses were also performed to evaluate the underlying mechanism. Results Due to the absorbance of Cu with the near-infrared laser irradiation, the injectable hydrogel exhibits persistent photothermal effect to kill cancer cells. In addition, the Cu of hydrogel shows the Fenton-like reaction to produce reactive oxygen species as chemodynamic therapy, thereby enhancing cancer treatment and amplifying ICD. More interestingly, we have found that the released NO can significantly increase depletion of CAFs and reduce the proportion of M2-type macrophages in vitro. Furthermore, due to the amplify of ICD, injectable hydrogel can effectively increase the infiltration of immune cells and reverse the immunosuppressive tumor microenvironment (TME) by regulating CAFs to enhance the therapeutic efficacy of anti-PD-L1 in vivo. Conclusions The ion induced self-assembled hydrogel with NO could enhance immunotherapy via amplifying ICD and regulating CAFs. It provides a novel strategy to provoke a robust antitumor immune response for clinical cancer immunotherapy. Graphical Abstract
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Pharmaceutical Science, Nanjing Tech University, Nanjing 211816, Jiangsu, China.

Funding

Natural Science Foundation of Jiangsu Province-Outstanding Youth Foundation · Life Science and Technology Project of Nanjing · National Natural Science Foundation of China · Jiangsu Synergetic Innovation Center for Advanced Bio-Manufacture

References (66)

Show source-provided references
1. 10.1016/j.cell.2018.09.03510.1016/j.cell.2018.09.035 ↗
2. 10.1186/s12943-021-01428-110.1186/s12943-021-01428-1 ↗
3. 10.1016/j.apsb.2021.05.01210.1016/j.apsb.2021.05.012 ↗
4. 10.1002/advs.20220173410.1002/advs.202201734 ↗
5. 10.1016/j.apsb.2021.05.00510.1016/j.apsb.2021.05.005 ↗
6. 10.1126/sciadv.add359910.1126/sciadv.add3599 ↗
7. 10.1016/j.jconrel.2022.03.05910.1016/j.jconrel.2022.03.059 ↗
8. 10.1016/j.jconrel.2020.06.01510.1016/j.jconrel.2020.06.015 ↗
9. 10.1016/j.apsb.2021.05.03110.1016/j.apsb.2021.05.031 ↗
10. 10.1002/smll.20180067810.1002/smll.201800678 ↗
11. 10.1016/j.carbpol.2022.12012310.1016/j.carbpol.2022.120123 ↗
12. 10.1186/s12951-021-00975-510.1186/s12951-021-00975-5 ↗
13. 10.1016/j.biomaterials.2011.12.02910.1016/j.biomaterials.2011.12.029 ↗
14. 10.1002/adma.20140299610.1002/adma.201402996 ↗
15. 10.1002/advs.20170089110.1002/advs.201700891 ↗
16. 10.1002/advs.20220170310.1002/advs.202201703 ↗
17. 10.1038/s41568-019-0238-110.1038/s41568-019-0238-1 ↗
18. 10.1186/s12885-015-1272-310.1186/s12885-015-1272-3 ↗
19. 10.1007/s10585-019-09966-110.1007/s10585-019-09966-1 ↗
20. 10.1186/s12951-022-01738-610.1186/s12951-022-01738-6 ↗
21. 10.3389/fimmu.2018.0041410.3389/fimmu.2018.00414 ↗
22. 10.1111/j.1365-2567.2006.02430.x10.1111/j.1365-2567.2006.02430.x ↗
23. 10.1016/j.it.2019.02.00310.1016/j.it.2019.02.003 ↗
24. 10.1038/s41392-021-00506-610.1038/s41392-021-00506-6 ↗
25. 10.1038/nri.2017.4910.1038/nri.2017.49 ↗
26. 10.1038/s41419-019-1435-210.1038/s41419-019-1435-2 ↗
27. 10.1016/j.ajpath.2010.11.01710.1016/j.ajpath.2010.11.017 ↗
28. 10.7150/thno.2147110.7150/thno.21471 ↗
29. 10.1038/s41591-018-0266-510.1038/s41591-018-0266-5 ↗
30. 10.1053/j.seminoncol.2015.05.01110.1053/j.seminoncol.2015.05.011 ↗
31. 10.1021/acsmacrolett.8b0019010.1021/acsmacrolett.8b00190 ↗
32. 10.1016/j.actbio.2021.09.05110.1016/j.actbio.2021.09.051 ↗
33. 10.1021/acsnano.1c0904810.1021/acsnano.1c09048 ↗
34. 10.1002/adma.20200037610.1002/adma.202000376 ↗
35. 10.1038/s41565-019-0570-310.1038/s41565-019-0570-3 ↗
36. 10.1016/j.biomaterials.2019.11929710.1016/j.biomaterials.2019.119297 ↗
37. 10.1021/acsnano.0c0168710.1021/acsnano.0c01687 ↗
38. 10.1002/adfm.20190878810.1002/adfm.201908788 ↗
39. 10.3390/pharmaceutics1407137710.3390/pharmaceutics14071377 ↗
40. 10.1186/s12951-023-01771-z10.1186/s12951-023-01771-z ↗
41. 10.1016/j.actbio.2022.08.07610.1016/j.actbio.2022.08.076 ↗
42. 10.1021/acsami.8b0712010.1021/acsami.8b07120 ↗
43. 10.1007/s00425-016-2501-y10.1007/s00425-016-2501-y ↗
44. 10.1021/acsnano.7b0687010.1021/acsnano.7b06870 ↗
45. 10.1016/j.biomaterials.2013.05.06310.1016/j.biomaterials.2013.05.063 ↗
46. Pelegrino MT De Araujo Lima B Do Nascimento MHM Lombello CB Brocchi M Seabra AB. Biocompatible and Antibacterial Nitric Oxide-Releasing Pluronic F-127/Chitosan Hydrogel for Topical Applications. Polymers (Basel). 2018;10:452.10.3390/polym10040452 ↗
47. 10.1039/C9SC01374A10.1039/C9SC01374A ↗
48. 10.1021/acsnano.1c0049810.1021/acsnano.1c00498 ↗
49. 10.1016/j.addr.2021.11400410.1016/j.addr.2021.114004 ↗
50. 10.1021/jacs.8b0871410.1021/jacs.8b08714 ↗
51. 10.3390/vetsci702005110.3390/vetsci7020051 ↗
52. 10.1021/acs.nanolett.9b0171710.1021/acs.nanolett.9b01717 ↗
53. 10.1002/jcb.2768110.1002/jcb.27681 ↗
54. 10.1038/s41598-018-20886-010.1038/s41598-018-20886-0 ↗
55. 10.1038/s41598-021-87791-x10.1038/s41598-021-87791-x ↗
56. 10.1038/s41577-019-0203-y10.1038/s41577-019-0203-y ↗
57. 10.1158/2159-8290.CD-19-138410.1158/2159-8290.CD-19-1384 ↗
58. 10.1016/j.bbrc.2020.08.01410.1016/j.bbrc.2020.08.014 ↗
59. 10.1111/j.1399-0039.2006.00590.x10.1111/j.1399-0039.2006.00590.x ↗
60. 10.1189/jlb.2HI1115-525R10.1189/jlb.2HI1115-525R ↗
61. Gordon S Maute R Dulken B Hutter G George B McCracken M Gupta R Tsai J Sinha R Corey D et al. PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity. Nat. 2017;545:495-9.10.1038/nature22396 ↗
62. 10.1038/s41598-019-39553-z10.1038/s41598-019-39553-z ↗
63. 10.3389/fimmu.2018.0118610.3389/fimmu.2018.01186 ↗
64. 10.1158/0008-5472.CAN-03-186010.1158/0008-5472.CAN-03-1860 ↗
65. 10.1016/j.jconrel.2011.06.00110.1016/j.jconrel.2011.06.001 ↗
66. 10.1074/jbc.M20240420010.1074/jbc.M202404200 ↗